4-乙基-2-吡咯烷酮 | 41819-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 4-乙基-2-吡咯烷酮
• 英文名称: 4-ethylpyrrolidin-2-one
• 英文别名: 4-ethyl-2-pyrrolidinone；4-ethyl-pyrrolidin-2-one；4-Aethyl-pyrrolidin-2-on
• CAS: 41819-75-4
• 化学式: C₆H₁₁NO
• mdl: MFCD09864500
• 分子量: 113.159
• InChiKey: ZBCUGJNJBOSHIA-UHFFFAOYSA-N

物化性质

• 熔点：
  39-41 °C
• 沸点：
  117-118 °C(Press: 13 Torr)
• 密度：
  0.952±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  4-乙基-2-吡咯烷酮 在 氯化铵 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 4-ethylpyrrolidin-2-imine, monohydrochloride
  参考文献：
  名称：

  2-Iminopyrrolidines as Potent and Selective Inhibitors of Human Inducible Nitric Oxide Synthase

  摘要：

  A series of substituted 2-iminopyrrolidines has been prepared and shown to be potent and selective inhibitors of the human inducible nitric oxide synthase (hiNOS) isoform versus the human endothelial nitric oxide synthase (heNOS) and the human neuronal nitric oxide synthase (hnNOS). Simple substitutions at the 3-, 4-, or 5-position afforded more potent analogues than the parent 2-iminopyrrolidine 1. The effect of ring substitutions on both potency and selectivity for the different NOS isoforms is described. Substitution at the 4- and 5-positions of the 2-iminopyrrolidine yielded both potent and selective inhibitors of hiNOS. In particular, (+)-cis-4-methyl-5-pentylpyrrolidin-2-imine, monohydrochloride (20), displayed potent inhibition of hiNOS (IC50 = 0.25 mu M) and selectivities of 897 (heNOS IC50/hiNOS IC50) and 13 (hnNOS IC50/hiNOS IC50) Example 20 was shown to be an efficacious inhibitor of NO production in the mouse endotoxin assay. Furthermore, 20 displayed in vivo selectivity, versus heNOS isoform, by not elevating blood pressure at multiples of the effective dose in the mouse.

  DOI：

  10.1021/jm970840x
• 作为产物：
  描述：

  反-2-戊酸甲酯 在 platinum(IV) oxide 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 4-乙基-2-吡咯烷酮
  参考文献：
  名称：

  Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase

  摘要：

  Syntheses and evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase (NOS) are discussed. An extensive SAR was established for pyrrolidin-2-imines class of compounds. The amidines came out as the most potent inhibitors in addition to displaying selectivity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.033

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• [EN] PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS<br/>[FR] COMPOSÉS PYRIMIDINYL-PYRIDYLOXY-NAPHTYLE ET PROCÉDÉS DE TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À IRE1
  申请人：GENENTECH INC

  公开号：WO2018166528A1

  公开（公告）日：2018-09-20

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有肌醇需要酶1（IRE1）调节活性或功能的嘧啶基-吡啶氧基-萘基化合物，其具有公式（I）或（I'）结构：或其立体异构体，互变异构体或药学上可接受的盐，并具有所述的取代基和结构特征。还描述了包括公式（I）或（I'）化合物的制药组合物和药物，以及使用这种IRE1调节剂的方法，单独或与其他治疗剂联合治疗介导或依赖于雌激素受体的疾病或病况。
• Pyrido [2,1-a] isoquinoline derivatives
  申请人：——

  公开号：US20040259903A1

  公开（公告）日：2004-12-23

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 and R 4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了式（I）的化合物，其中R1、R2、R3和R4如描述中所示，或其药学上可接受的盐。这些化合物可用于治疗与DPP-IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140045855A1

  公开（公告）日：2014-02-13

  Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的Chroman化合物和衍生物是TRPM8的有用抑制剂。这些化合物在治疗多种由TRPM8介导的疾病和症状方面具有用途，并可用于制备治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括，但不限于，偏头痛和神经病性疼痛。Formula I的化合物具有以下结构：变量的定义在此提供。
• PROCESS FOR PREPARING LACTAMS
  申请人：RHODIA OPERATIONS

  公开号：US20150051401A1

  公开（公告）日：2015-02-19

  The present invention relates to a method for preparing lactams using heterogeneous catalysis by hydrogenating at least one compound of the following formula (I), where A is a radical of the following formula (I′) or (II′): —CH(R 1 )—CH(R 2 )— (I′); or —CH(R 1 )—CH(R 2 )—CH(R 3 )— (II′); where R 1 , R 2 and R 3 are, independently from each other, H, OH, an alkyl radical, or a cycloalkyl radical; and R is H or a straight or branched alkyl radical having 1 to 20, preferably 1 to 10, and more preferably 1 to 4 carbon atoms. Said method is carried out at a pressure of less than 60 bars, preferably 10 to 50 bars, in the presence of a solid hydrogenation catalyst including at least two metals selected from the group of noble metals and transition metals, and an inert substance used as a support, wherein said compound of formula (I) can be used alone or as part of a mixture.

  本发明涉及一种利用异质催化制备内酰胺的方法，通过氢化至少一种以下式(I)的化合物来实现，其中A是以下式(I′)或(II′)的基团：—CH(R1)—CH(R2)—(I′)；或—CH(R1)—CH(R2)—CH(R3)—(II′)；其中R1、R2和R3独立于彼此，为H、OH、烷基基团或环烷基基团；而R为H或具有1至20个碳原子、优选为1至10个碳原子、更优选为1至4个碳原子的直链或支链烷基基团。该方法在低于60巴的压力下进行，优选在10至50巴的压力下，在固体氢化催化剂的存在下进行，所述固体氢化催化剂包括从贵金属和过渡金属组中选择的至少两种金属，以及作为支撑物质的惰性物质，其中所述的式(I)化合物可以单独使用或作为混合物的一部分。